ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SNDZ Sunridge International Inc (CE)

0.0001
0.00 (0.00%)
07 Feb 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunridge International Inc (CE) USOTC:SNDZ OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0001 0.00 00:00:00

Sunridge Moves Forward to Open Company Owned Clinics

13/01/2011 2:00pm

PR Newswire (US)


Sunridge (CE) (USOTC:SNDZ)
Historical Stock Chart


From Feb 2020 to Feb 2025

Click Here for more Sunridge (CE) Charts.

FOUNTAIN HILLS, Ariz., Jan. 13, 2011 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ), announced today that it plans to open company owned glaucoma clinics for the use of its patented treatment Pneumatic Trabeculoplasty (PNT).  

As a manufacturer, Sunridge currently relies on its distributor network for sales.  Though the company is in the process of expanding its distributor network, it is still reliant on others to provide profitability for the company.  It is the company's intent to take advantage of its patented procedure by initiating glaucoma clinics under its direct control.  By doing so, Sunridge can capitalize not only on the sales of its equipment and disposable product line to others, but also a direct revenue source from our clinics for the medical treatment itself.  

Sunridge is currently raising money to open its first clinic.  Based on past experience our projections for the clinic would indicate that it would be cash flow positive by its fourth month of operation.  Once successful with the first clinic, Sunridge intends to raise capital for the rapid expansion of additional company owned clinics.  This new direction in the company's business plan allows us to take direct charge of our future and accelerate profitability for the company.

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.

CONTACT:

Jeff Smith

Sunridge International

T:  +1-480-837-6165

e-mail: info@sunridgeint.com

Website: www.sunridgeint.com



MEDIA:

Victor Webb

Marston Webb International

T: (212) 684-6601

e-mail: marwebint@cs.com





SOURCE Sunridge International

Copyright 2011 PR Newswire

1 Year Sunridge (CE) Chart

1 Year Sunridge (CE) Chart

1 Month Sunridge (CE) Chart

1 Month Sunridge (CE) Chart

Your Recent History

Delayed Upgrade Clock